Acetadote (acetylcysteine) Injection

Published Online: Monday, May 1, 2006

Cumberland Pharmaceuticals (Nashville, Tenn) recently received FDA approval for revised labeling for Acetadote Injection. The product is used in an emergency room setting to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many OTC painkillers. Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. The revised package insert includes a dosage guide for pediatric patients who weigh <40 kg. The loading dose (300 mg/kg) administration also has been extended to 60 minutes, making the total recommended treatment time 21 hours. Acetadote is available as a 20% solution in 30-mL (200 mg/mL) single-dose vials. For more information, visit, or call 877-484-2700.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues